Blue Cross partners with Onduo to provide diabetes management wearable

Cara Livernois | | Health Exec | Economics

Blue Cross and Blue Shield has announced a partnership with Onduo, an Alphabet-backed wearable device for the monitoring of glucose levels in diabetic patients.

A year after the launch of Onduo by Alphabet, with the aim to produce technologies for the improved self-management of diabetes, the partnership with Blue Cross will provide individuals the ability to improve health outcomes with the technology.

“We’re working on finding those innovations in the market that will move the needle and improve our (health plan) members' lives,” said Maureen Sullivan, Blue Cross and Blue Shield Association senior vice president and chief strategy officer.

Read the full story below:

Blue Cross Plans Partner With Alphabet Venture To Manage Diabetes

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Cardiologist sues health system over gender discrimination, unequal pay and hostile treatment
FTC, DOJ and HHS release report warning of private equity consolidation in healthcare
Q&A: Vulnerable patients hit hardest by anesthesia reimbursement cuts
Momentum continues for renal denervation as CMS considers national Medicare coverage
Johnson & Johnson buys depression drug and its manufacturer for $15B
UnitedHealth, Amedisys ask federal judge to dismiss DOJ lawsuit blocking $3.3B merger

Around the web

AI in Healthcare
Nat’l Academy of Medicine sets ‘priorities for action’ as healthcare mulls next moves with AI

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.